Irish biopharmaceutical company Amarin has continued a patent battle over its fish oil product Vascepa (icosapent ethyl), with a lawsuit targeting Teva in Nevada.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 April 2020 A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
1 April 2020 A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.
1 April 2020 A US judge has opened the door to generic versions of heart disease drug Vascepa, after invalidating Amarin’s key patents covering the drug.